[go: up one dir, main page]

AR060130A1 - FORMULATION OF AN ANTI-IGF-1R HUMAN MONOCLONAL ANTIBODY - Google Patents

FORMULATION OF AN ANTI-IGF-1R HUMAN MONOCLONAL ANTIBODY

Info

Publication number
AR060130A1
AR060130A1 ARP070101241A ARP070101241A AR060130A1 AR 060130 A1 AR060130 A1 AR 060130A1 AR P070101241 A ARP070101241 A AR P070101241A AR P070101241 A ARP070101241 A AR P070101241A AR 060130 A1 AR060130 A1 AR 060130A1
Authority
AR
Argentina
Prior art keywords
igf
formulation
monoclonal antibody
human monoclonal
preparation
Prior art date
Application number
ARP070101241A
Other languages
Spanish (es)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR060130A1 publication Critical patent/AR060130A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invencion está relacionada con una formulacion de anticuerpo monoclonal humano anti-IGF-1R, un proceso para la preparacion y usos del mismo.The present invention is related to a formulation of anti-IGF-1R human monoclonal antibody, a process for the preparation and uses thereof.

ARP070101241A 2006-03-28 2007-03-26 FORMULATION OF AN ANTI-IGF-1R HUMAN MONOCLONAL ANTIBODY AR060130A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06111848 2006-03-28

Publications (1)

Publication Number Publication Date
AR060130A1 true AR060130A1 (en) 2008-05-28

Family

ID=37025222

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070101241A AR060130A1 (en) 2006-03-28 2007-03-26 FORMULATION OF AN ANTI-IGF-1R HUMAN MONOCLONAL ANTIBODY

Country Status (18)

Country Link
EP (1) EP1998806A1 (en)
JP (1) JP2009531371A (en)
KR (1) KR20080104160A (en)
CN (1) CN101410137A (en)
AR (1) AR060130A1 (en)
AU (1) AU2007229554A1 (en)
BR (1) BRPI0709229A2 (en)
CA (1) CA2647111A1 (en)
CL (1) CL2007000797A1 (en)
CR (1) CR10295A (en)
EC (1) ECSP088778A (en)
IL (1) IL193904A0 (en)
MA (1) MA30345B1 (en)
MX (1) MX2008012295A (en)
NO (1) NO20083895L (en)
RU (1) RU2008142359A (en)
TW (1) TW200815029A (en)
WO (1) WO2007110339A1 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2671968A1 (en) * 2006-12-11 2008-06-19 F. Hoffmann-La Roche Ag Abeta antibody parenteral formulation
GB0702888D0 (en) * 2007-02-14 2007-03-28 Glaxo Group Ltd Novel Antibodies
MX2009010179A (en) * 2007-03-22 2010-03-15 Imclone Llc Stable antibody formulations.
CN101687038A (en) * 2007-07-10 2010-03-31 霍夫曼-拉罗奇有限公司 Novel formulation
US20100249384A1 (en) * 2007-11-29 2010-09-30 Stefan Hepbildikler Immunoglobulin aggregates
NZ585516A (en) * 2007-12-21 2012-07-27 Hoffmann La Roche Anti-cd20 antibody formulation
WO2010069858A1 (en) * 2008-12-19 2010-06-24 F. Hoffmann-La Roche Ag Pharmaceutical composition
WO2010146059A2 (en) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarkers for igf-1r inhibitor therapy
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AR078161A1 (en) 2009-09-11 2011-10-19 Hoffmann La Roche VERY CONCENTRATED PHARMACEUTICAL FORMULATIONS OF AN ANTIBODY ANTI CD20. USE OF THE FORMULATION. TREATMENT METHOD
EP2519262A2 (en) * 2009-12-29 2012-11-07 F. Hoffmann-La Roche AG Antibody formulation
US20130136733A1 (en) * 2010-05-28 2013-05-30 Novo Nordisk A/S Stable Multi-Dose Compositions Comprising an Antibody and a Preservative
KR102031020B1 (en) 2011-03-31 2019-10-14 머크 샤프 앤드 돔 코포레이션 Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
CN102363040B (en) * 2011-10-21 2013-05-01 北京锐瑟科技有限公司 Antimicrobial peptide preparation for mucosal tissues
US20160068613A1 (en) 2013-04-29 2016-03-10 Hoffmann-La Roche Inc. Fc-receptor binding modified asymmetric antibodies and methods of use
KR20210094669A (en) 2013-04-29 2021-07-29 에프. 호프만-라 로슈 아게 Human fcrn-binding modified antibodies and methods of use
CN103505729B (en) * 2013-05-24 2015-10-28 华北制药集团新药研究开发有限责任公司 A kind of stable rabies virus human antibody combination preparation
CN104707146B (en) * 2013-12-16 2019-04-16 浙江海正药业股份有限公司 A kind of pharmaceutical composition containing adalimumab
MX380658B (en) 2014-01-15 2025-03-11 Hoffmann La Roche REGION FC VARIANTS WITH ENHANCED PROTEIN A BINDING.
JP6707469B2 (en) * 2014-05-28 2020-06-10 ノノ インコーポレイテッド Lyophilized formulation of Tat-NR2B9c containing acetylated scavenger
TW201628649A (en) 2014-10-09 2016-08-16 再生元醫藥公司 Method for reducing microscopic particles in a pharmaceutical formulation
AR103173A1 (en) 2014-12-22 2017-04-19 Novarits Ag PHARMACEUTICAL PRODUCTS AND STABLE LIQUID COMPOSITIONS OF ANTIBODIES IL-17
IL302486A (en) 2015-06-24 2023-06-01 Hoffmann La Roche Anti-transferrin receptor antibodies with tailored affinity
RU2731418C2 (en) * 2015-09-28 2020-09-02 Сучжоу Санкадия Биофармасьютикалз Ко., Лтд. Stable pharmaceutical preparation based on the pd-1 antibody and its use in medicine
AR106189A1 (en) 2015-10-02 2017-12-20 Hoffmann La Roche BIESPECTIFIC ANTIBODIES AGAINST HUMAN A-b AND THE HUMAN TRANSFERRINE RECEIVER AND METHODS OF USE
CN114057885A (en) 2015-10-02 2022-02-18 豪夫迈·罗氏有限公司 Bispecific anti-human CD20/human transferrin receptor antibody and methods of use
CN106199007B (en) * 2016-08-03 2017-04-05 烟台普罗吉生物科技发展有限公司 Protein protective agent
SG11201900201YA (en) 2016-08-16 2019-02-27 Regeneron Pharma Methods for quantitating individual antibodies from a mixture
AU2017350807B2 (en) 2016-10-25 2022-07-07 Regeneron Pharmaceuticals, Inc. Methods and systems for chromatography data analysis
JOP20190260A1 (en) 2017-05-02 2019-10-31 Merck Sharp & Dohme Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
WO2018204374A1 (en) 2017-05-02 2018-11-08 Merck Sharp & Dohme Corp. Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
CN118416215A (en) 2017-09-19 2024-08-02 里珍纳龙药品有限公司 Methods for reducing particle formation and compositions formed therefrom
TWI853823B (en) 2018-07-02 2024-09-01 美商里珍納龍藥品有限公司 Systems and methods for preparing a polypeptide from a mixture
KR20210089215A (en) 2018-11-07 2021-07-15 머크 샤프 앤드 돔 코포레이션 Co-Formulation of Anti-LAG3 Antibody and Anti-PD-1 Antibody
CN114324882B (en) * 2020-10-12 2022-12-27 广东菲鹏生物有限公司 Protein stabilizer and application thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3919235B2 (en) * 1997-06-13 2007-05-23 ジェネンテク，インコーポレイテッド Antibody preparation
UY27087A1 (en) * 2001-01-05 2002-06-20 Pfizer ANTIBODIES AGAINST THE RECEIVER OF THE SIMILAR TO INSULIN GROWTH FACTOR
CA2454587C (en) * 2001-07-25 2012-11-13 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
JP4473257B2 (en) * 2003-04-02 2010-06-02 エフ．ホフマン−ラ ロシュ アーゲー Antibodies to insulin-like growth factor I receptor and uses thereof
DK2335725T3 (en) * 2003-04-04 2017-01-23 Genentech Inc Highly concentrated antibody and protein formulations
US7579157B2 (en) * 2003-07-10 2009-08-25 Hoffmann-La Roche Inc. Antibody selection method against IGF-IR
ES2351395T3 (en) * 2003-08-13 2011-02-04 Pfizer Products Inc. ANTI-IGF-1R MODIFIED HUMAN ANTIBODIES.

Also Published As

Publication number Publication date
NO20083895L (en) 2008-10-24
IL193904A0 (en) 2011-08-01
CN101410137A (en) 2009-04-15
CR10295A (en) 2008-10-06
AU2007229554A1 (en) 2007-10-04
MX2008012295A (en) 2008-10-09
MA30345B1 (en) 2009-04-01
EP1998806A1 (en) 2008-12-10
JP2009531371A (en) 2009-09-03
RU2008142359A (en) 2010-05-10
BRPI0709229A2 (en) 2011-06-28
WO2007110339A1 (en) 2007-10-04
CL2007000797A1 (en) 2008-01-25
KR20080104160A (en) 2008-12-01
ECSP088778A (en) 2008-10-31
TW200815029A (en) 2008-04-01
CA2647111A1 (en) 2007-10-04

Similar Documents

Publication Publication Date Title
AR060130A1 (en) FORMULATION OF AN ANTI-IGF-1R HUMAN MONOCLONAL ANTIBODY
ECSP10010295A (en) FORMULATION OF ANTIBODY
MX353706B (en) ANTIBODIES AGAINST HUMAN CSF-1R AND USES OF THE SAME.
AR057807A1 (en) ANTI-CD3 ANTIBODY FORMULATIONS
CR20120310A (en) NEUTRALIZING ANTIBODIES AGAINST THE PROLACTIN RECEPTOR AND THERAPEUTIC USE
CR20150625A (en) COMPOSITION UNDERSTANDING ANTIBODY FIXED TO DOMAIN II OF HER2 AND ITS VARIOUS ACIDS
CR20160355A (en) NEUTRALIZING ANTIBODIES OF HUMAN ATOMEGALOVIRUS AND USE OF THE SAME
EA200900040A1 (en) ANTIBODY MOLECULES THAT ASSOCIATE WITH HUMAN IL-17
ECSP13012877A (en) SOLID FORMS SDE 3- (5-AMINO-2-methyl -4- oxo-4H-QUINAZOL1N-3-IL) - PIPERIDIN-2, 6-DIONA, AND ITS PHARMACEUTICAL COMPOSITIONS AND USES
CR10528A (en) PROCESS TO PRODUCE POXVIRUS AND POXVIRUS COMPOSITIONS
CL2019001745A1 (en) Conjugated antibody drug for ablation of hematopoietic stem cells.
PA8772101A1 (en) IMIDAZOL-TRIAZOLOPIRIMIDINAS REPLACED
UY31466A1 (en) MONOCLONAL ANTIBODIES THAT JOIN THE HGM-CSF AND THE MEDICAL COMPOSITIONS THAT UNDERSTAND THEM
AR051484A1 (en) ANTIBODY MOLECULES THAT HAVE SPECIFICITY FOR IL - 17 HUMAN
CO7151488A2 (en) Anti-jagged1 / jagged 2 cross-reaction antibodies, activatable anti-jagged antibodies and methods of use thereof
ECSP14000329A (en) MOLECULES THAT ARE ANTIBODIES WITH SPECIFICITY FOR HUMAN OX40
MX353827B (en) Forms of rifaximin and uses thereof.
CR20110466A (en) ANTI-ERBB-3 / ANTI-C-MET ANTI-ERBB ANTIBODIES
CO6362023A2 (en) ANTI-EGFR / ANTI-IGF-1R BIESPECIFIC ANTIBODIES
PA8770101A1 (en) AMIDAS OF 4-ARIL-1,4-DIHIDRO-1, 6-NAFTIRIDINE SUBSTITUTED AND ITS USE
EA201001577A1 (en) DPP-4 INHIBITOR IN A COMBINATION WITH AN ADDITIONAL ANTI-DIABETIC AGENT, TABLETS INCLUDING THE SPECIFIED COMPOSITIONS, THEIR APPLICATION AND METHOD OF THEIR PRODUCTION
ECSP088613A (en) ANTIBODY MOLECULES THAT HAVE SPECIFICITY FOR HUMAN IL-6
BRPI1014544B8 (en) isolated fully human monoclonal anti-il-17f antibody and pharmaceutical composition comprising the same
LT2013015A (en) PHARMACEUTICAL COMPOSITIONS
CR10561A (en) VACCINES FOR MALARIA

Legal Events

Date Code Title Description
FA Abandonment or withdrawal